This is a phase 3 study to evaluate effects on proteinuria and glomerular filtration rate of sibeprenlimab 400 mg subcutaneously (s.c.) Q 4 weeks in adults with IgAN who are receiving maximally tolerated standard-of-care therapy.

Conditions

  • Immunoglobulin A Nephropathy

Intervention

  • Sibeprenlimab 400 mg
  • Placebo

Principal Investigator

  • Norouzi, Sayna

Sponsor

  • Otsuka Pharmaceutical Development & Commercialization, Inc.

*The source of data for this particular study is "ClinicalTrials.gov" and was last updated on 05/16/2024. Loma Linda University does not make any warranties, expressed or implied, with respect to such data, and, furthermore, assumes no liability for any party's use, or the results of such use of the data.

Request Information

Complete the form below to contact the study team and receive more information about this trial.